Daily close, T-120 (5/9/25) through T+5. Run-up high $17.04 on 9/5/25, low $8.73 on 7/8/25 (T-120 to T-1). FDA decision 10/24/25. Historical price action, not a forecast.
Positioning before the decision
On Oct 10, 2025, 14 days before the decision date, at-the-money options priced a move of ±26.9% through Nov 21, 2025 (the first listed expiry after the decision; ATM implied volatility 100%). The stock closed -7.8% at the first close across the decision and -8.8% five trading days on. A straddle priced weeks out covers ordinary movement plus the event, so this is the move the options market priced through that expiry, not the event-implied move alone. How this compares across 1,000+ decisions.
Was Revuforj (revumenib) - (AUGMENT-101) approved by the FDA?
Yes. The FDA approved the application for Revuforj (revumenib) - (AUGMENT-101) on October 24, 2025. The primary source is linked on this page.
What was Revuforj (revumenib) - (AUGMENT-101) under FDA review for?
The application covered Relapsed/refractory (R/R) acute leukemias. The FDA approved the application on October 24, 2025.
How did SNDX stock react to the FDA decision?
On the decision day SNDX moved -7.8%. That is the recorded reaction to this specific event -- historical measurement, not a prediction, and not investment advice.